Drugs / IBI389
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05164458 | Mar 2022 → Apr 2024 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI389 | “IBI389 is a novel anti-Claudin18.2 × CD3 bispecific antibody designed to engage T cells by binding CD3 and Claudin18.2, thereby induce immune synapse formation.” PMID 41540424 ↗ Jan 2026 |
| Route | Intravenous | “IBI 389 IV Q2\~Q3W Day 1” NCT05164458 ↗ |